1-叔-丁基环己烷羧酸 | 27334-43-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-叔-丁基环己烷羧酸
• 英文名称: 1-tert-butyl-1-cyclohexyl-carboxylic acid
• 英文别名: 1-tert-butylcyclohexane carboxylic acid；1-tert.-Butylcyclohexancarbonsaeure；1-tert-Butylcyclohexansaeure；Cyclohexanecarboxylic acid, 1-(1,1-dimethylethyl)-；1-tert-butylcyclohexane-1-carboxylic acid
• CAS: 27334-43-6
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.279
• InChiKey: NPRFVBVVQXZPOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916209090

反应信息

• 作为反应物：
  描述：

  1-叔-丁基环己烷羧酸 在 lithium aluminium tetrahydride 作用下， 以 二丁醚 为溶剂， 生成 (1-tert-Butylcyclohexyl)methanol
  参考文献：
  名称：

  Peters,J.A.; van Bekkum,H., Recueil des Travaux Chimiques des Pays-Bas, 1973, vol. 92, p. 379 - 392

  摘要：

  DOI：
• 作为产物：
  描述：

  甲酸 、 4-叔丁基环己醇 以 四氯化碳 为溶剂， 生成 1-叔-丁基环己烷羧酸
  参考文献：
  名称：

  van Bekkum,H. et al., Recueil des Travaux Chimiques des Pays-Bas, 1970, vol. 89, p. 521 - 534

  摘要：

  DOI：

文献信息

• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• 1-tert-Butylcyclohexanecarboxamide and uses thereof as cooling compounds
  申请人：Kazimierski Arkadiusz

  公开号：US20110070329A1

  公开（公告）日：2011-03-24

  Described is a new cooling agent represented by Formula I and compositions with known coolers having cooling properties and the application of Formula I in foodstuffs and chewing gum: wherein X, Y is independently selected from a C1-C4 straight or branched alkyl or H atom; and m is 0, 1 or 2, Z when present is nitrogen, W and W′ are selected independently from the group consisting of H, OH, C1-C4 straight or branched alkyl, and a C1-C4 straight or branched alkoxy or W is group (CH 2 )n-R, where n is 0 or 1 and R is a group with non-bonding electrons. Useful groups with non-bonding electrons are halogens, OH, OMe, OEt, NO 2 , CN, Ac, SO 2 NH 2 , CHO, CO 2 H, CONH 2 , CONHR 2 , where R 2 is selected from C1-C4, and C1-C4 alkyl carboxylates such as CO 2 Me or CO 2 Et.

  描述了一种由化学式I代表的新冷却剂，以及具有冷却性能的已知冷却剂的组合物，以及化学式I在食品和口香糖中的应用：其中X、Y分别选自C1-C4直链或支链烷基或氢原子；m为0、1或2，Z存在时为氮，W和W′分别选自H、OH、C1-C4直链或支链烷基，以及C1-C4直链或支链烷氧基，或者W为基团(CH2)n-R，其中n为0或1，R是具有非成键电子的基团。具有非成键电子的有用基团包括卤素、OH、OMe、OEt、NO2、CN、Ac、SO2NH2、CHO、CO2H、CONH2、CONHR2，其中R2选自C1-C4烷基，以及C1-C4烷基羧酸酯，如CO2Me或CO2Et。
• Pharmaceutically active cyclohexyl compounds and their preparation
  申请人：Labaz

  公开号：US04283420A1

  公开（公告）日：1981-08-11

  The chemical compounds of the invention are useful as the active compound in drugs because of their anticonvulsant and/or antianoxic activity. They have the general formula ##STR1## wherein Z is a hydroxyl group; a group--OM wherein M is an alkali metal atom or an equivalent atom fraction of an alkaline-earth metal or an amino group such as --NH.sub.2, and R is a linear or branched alkyl group containing from 1 to 9 carbon atoms, and optionally substituted by one or more halogen atoms; a linear or branched alkenyl or alkynyl, alkoxyalkyl, or acylalkyl group containing from 2 to 9 carbon atoms and optionally substituted by one or more halogen atoms; an aryl or arylalkyl or aryloxyalkyl group comprising at least one aromatic radical and an alkyl chain having from 1 to 4 carbon atoms.

  该发明的化合物由于其抗惊厥和/或抗缺氧活性，在药物中作为活性化合物是有用的。它们具有以下通式：##STR1## 其中Z是羟基；一个--OM基团，其中M是碱金属原子或碱土金属的等价原子分数，或者是氨基基团，例如--NH.sub.2，而R是含有1至9个碳原子的线性或支链烷基，并且可以被一个或多个卤素原子取代；含有2至9个碳原子的线性或支链烯基或炔基，烷氧基烷基或酰基烷基基团，并且可以被一个或多个卤素原子取代；包含至少一个芳香基团和一个具有1至4个碳原子的烷基链的芳基或芳基烷基或芳氧基烷基基团。
• ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：PERNERSTORFER Josef

  公开号：US20120264790A1

  公开（公告）日：2012-10-18

  The present invention relates to compounds of the formula I, wherein A, Y, Z, R 20 to R 22 and R 50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA 1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及公式I的化合物，其中A、Y、Z、R20至R22和R50在权利要求中所示，它们是有价值的药物活性化合物。具体来说，它们是内皮分化基因受体2（Edg-2、EDG2）的抑制剂，该受体被溶血磷脂酸（LPA）激活，也被称为LPA1受体，可用于治疗动脉粥样硬化、心肌梗死和心力衰竭等疾病。本发明还涉及制备公式I化合物的方法，它们的用途以及包含它们的药物组合物。
• MODIFIED NANOCELLULOSE, AND RESIN COMPOSITION CONTAINING MODIFIED NANOCELLULOSE
  申请人：DIC CORPORATION

  公开号：US20150376298A1

  公开（公告）日：2015-12-31

  The present invention provides a novel modified nanocellulose suitable for surface modification of nanocellulose or introduction of functional groups into nanocellulose, and a resin composition comprising the modified nanocellulose. More specifically, the present invention provides a modified nanocellulose in which a portion of the hydroxyl groups of cellulose constituting nanocellulose is substituted with at least one substituent represented by formula (1), and a resin composition comprising the modified nanocellulose and a resin.

  本发明提供了一种新型的改性纳米纤维素，适用于表面改性纳米纤维素或将功能基团引入纳米纤维素，并包括改性纳米纤维素的树脂组成物。更具体地说，本发明提供了一种改性纳米纤维素，其中构成纳米纤维素的纤维素的一部分羟基被至少一个由式（1）表示的取代基所取代，以及包括改性纳米纤维素和树脂的树脂组成物。